Affiliation
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.Issue Date
1995-01
Metadata
Show full item recordAbstract
Blood progenitor cells (BPC) are increasingly used in a variety of clinical settings. These include autologous and allogeneic transplantation after myeloablative therapy, and gene therapy. The optimal blood products for each of these applications have not been defined. The use of different cytotoxic drugs and cytokines, alone and in combination, results in the mobilisation of different total numbers and relative proportions of primitive and committed BPC. Some cytotoxics and cytokines not only are poor at mobilising BPC, but also are myelotoxic. Here we review the biology of BPC mobilisation and its implications for their clinical use.Citation
Biology of blood progenitor cells used in transplantation. 1995, 61 (1):1-15 Int. J. Hematol.Journal
International Journal of HematologyPubMed ID
7718764Type
ArticleLanguage
enISSN
0925-5710Related articles
- Cytokines in haemopoietic progenitor mobilisation for peripheral blood stem cell transplantation.
- Authors: Filshie RJ
- Issue date: 2002
- The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
- Authors: Haas R, Murea S
- Issue date: 1995 Dec
- Expanding the role of blood progenitor cells.
- Authors: Pettengell R
- Issue date: 1995 Oct
- Practical applications for peripheral blood progenitor cells in the treatment of lymphomas and solid tumours.
- Authors: Pettengell R
- Issue date: 1995
- The whys and hows of hematopoietic progenitor and stem cell mobilization.
- Authors: Kessinger A, Sharp JG
- Issue date: 2003 Mar